Veracyte SEC Filings

Veracyte (VCYT) reports a proposed sale of 2,160 common shares, representing restricted stock units acquired on 03/02/2025, with an aggregate market value of $74,152.80. The shares are to be sold through Morgan Stanley Smith Barney LLC on or about 10/01/2025 on the NASDAQ. The issuer's outstanding shares are listed as 78,671,588, so the proposed sale equals approximately 0.0027% of outstanding shares. The filing also discloses prior 10b5-1 sales by the same account of 2,283 shares on 09/19/2025 for gross proceeds of $76,919.50. The securities were acquired as Restricted Stock Units from the issuer and no cash payment was required at acquisition.

Annie McGuire, SVP and General Counsel of Veracyte, Inc. (VCYT), reported the sale of 2,283 shares of Veracyte common stock on 09/19/2025 under a pre-established Rule 10b5-1 plan adopted on 09/04/2024. The filing shows a weighted-average sale price of $33.6923 per share, with individual sale prices ranging from $33.50 to $34.00. After the transaction, Ms. McGuire beneficially owned 91,599 shares, reported as direct ownership.

The Form 4 was executed by an attorney-in-fact and explicitly states the sale was made pursuant to the 10b5-1 plan; additional per-price share breakdowns are available on request to the SEC, the issuer, or a shareholder.

Form 144 notice for Veracyte, Inc. (VCYT) reporting a proposed sale of 2,283 common shares, with an aggregate market value of $75,864.09, scheduled approximately for 09/19/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The shares were acquired as restricted stock units on 06/02/2025 from the issuer and were fully issued on that date. The filer certifies there are no undisclosed material adverse facts and reports no other sales by the same person in the past three months. The filing provides basic transactional details but does not state the seller's identity or motivation for the sale.

Marc Stapley, Chief Executive Officer and Director of Veracyte, Inc. (VCYT), sold 7,667 shares of the company's common stock on 09/04/2025 under a pre-established Rule 10b5-1 trading plan adopted on 09/13/2024. The transaction was reported at a weighted-average sale price of $30.4073, with individual sale prices ranging from $30.22 to $30.66. After the reported sale, the filing shows Mr. Stapley beneficially owns 334,185 shares. The Form 4 was executed by an attorney-in-fact and includes customary disclosure that detailed per-price share breakdowns are available upon request.

Rebecca Chambers, Chief Financial Officer of Veracyte, Inc. (VCYT), reported a Form 4 disclosing that on 09/02/2025 5,371 shares of Common Stock were withheld to satisfy tax withholding obligations related to the vesting of restricted stock units. The filing shows 133,158 shares of Common Stock beneficially owned by the reporting person after the transaction. The transaction code is noted as F and the per-share price listed is $30.11, with the filer confirming the withholding was not a sale but a tax-related retention of shares.

Annie McGuire, SVP and General Counsel of Veracyte, Inc. (VCYT), reported that 3,507 shares of common stock were withheld on 09/02/2025 to satisfy tax withholding tied to the vesting of restricted stock units; this withholding is not a sale and was executed at a per-share price of $30.11. After the withholding, McGuire beneficially owned 93,882 shares, which includes 386 shares purchased on 07/31/2025 under the company’s Employee Stock Purchase Plan. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/04/2025.

Marc Stapley, who is listed as both Chief Executive Officer and a director of Veracyte, Inc. (VCYT), reported a non-sale withholding of 7,914 shares of common stock on 09/02/2025 at an attributable price of $30.11 per share. The withholding satisfied tax obligations arising from the vesting of restricted stock units and therefore was not a market sale. After the transaction Stapley beneficially owned 341,852 shares, which includes 529 shares purchased on 07/31/2025 under the company’s Employee Stock Purchase Plan. The Form 4 was signed by an attorney-in-fact on 09/04/2025.

Veracyte insider Phillip G. Febbo reported a non-sale disposition of 2,955 shares of common stock on 09/02/2025. The transaction reflects shares withheld to satisfy tax withholding obligations related to the vesting of restricted stock units, executed at a reported price of $30.11 per share. After the withholding, the reporting person beneficially owns 100,790 shares. The Form 4 was signed by an attorney-in-fact on 09/04/2025 and identifies Febbo as the company’s Chief Scientific & Medical Officer and an officer of Veracyte (VCYT).

John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc. (VCYT), reported a transaction dated 09/02/2025 in which 2,902 shares of the company's common stock were withheld at a price of $30.11 to satisfy tax withholding obligations related to the vesting of restricted stock units. The filing clarifies that the withheld shares do not represent a sale. After the withholding, the reporting person beneficially owned 91,638 shares, held directly. The Form 4 was signed by an attorney-in-fact, Jonathan Wygant, on 09/04/2025. The form indicates the filing was made by one reporting person and identifies the reporting persons address as South San Francisco, CA.